Compare Sony Group Corp (SONY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sony Group Corp vs Zimmer Biomet Holdings Inc — how do they compare? Sony Group Corp trades at $23.5 (market cap $137.98B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $18.05B). The key difference: Sony Group Corp is far larger — about 7.6× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.01%). Which is the better fit depends on your goals.
| SONY | ZBH | |
|---|---|---|
Market Cap | $137.98B | $18.05B |
Sector | Technology | Health |
52-Week High | $30.26 | $104.26 |
52-Week Low | $19.32 | $79.58 |
Enterprise Value | $135.82B | $25.11B |
Dividend Yield | 0.68% | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sony's stock trades at $23.53, down 4.19% over 24 hours amid bearish technical signals. The company maintains strong operating cash flow of $2.32T for 2025 and beat earnings expectations in two of the last three quarters. However, negative net income margin of -1.75% and projected 2026 net loss of $221.6B raise concerns about near-term profitability despite analyst optimism.
The stock faces headwinds from technical weakness and projected earnings decline, but strong analyst support (68.75% buy ratings) and robust entertainment ecosystem provide long-term potential. Key risks include streaming competition and AI copyright litigation, while valuation metrics remain reasonable with P/E of 19.72 and EV/EBITDA of 7.71.
ZBH trades at $94.22, down 3.93% on the day, with a bearish technical signal but oversold RSI readings. Recent earnings beats and raised 2026 guidance support fundamentals, with revenue growth and strong gross margins. Leadership promotions aim to accelerate commercial transformation, while cash flow trends show operational strength.
The stock offers upside to the $104.88 consensus target, but faces headwinds from debt levels and competitive pressures. Near-term support at $92 is critical; a hold rating aligns with mixed analyst views. Earnings execution and procedure demand growth are key catalysts for valuation expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
